A lab's interpretation that an STK11 variant of uncertain significance is likely pathogenic supports a young woman's ...

A recent paper has shed more light on how corticosteroids frequently prescribed to lung cancer patients could inhibit the ...

The company is testing its lead asset, a CAR T/NK-cell therapy, in a Phase I trial in patients with B-cell malignancies.

Researchers led by the nonprofit 4YouandMe and Mount Sinai want to identify second-site suppressor mutations as drug targets ...

NEW YORK – Kelonia Therapeutics this week said it has started treating patients with relapsed and refractory multiple myeloma in a Phase I trial of its in vivo CAR T-cell therapy KLN-1010.

Researchers hope to test the product's ability to clear symptoms in patients with the rare genetic disorder driven by RPS19 ...

NEW YORK – Krystal Biotech has discontinued a Phase I/II clinical trial evaluating an injected version of its gene therapy KB707 in locally advanced or metastatic solid tumors, including melanoma.

The latest report from the Make-an-IMPACT program focused on results delivered for pediatric cancer patients across 11 ...

BUFFALO, New York – Five major research centers in New York have banded together to share resources and a manufacturing ...

NEW YORK – ALX Oncology is transitioning from a broad immuno-oncology strategy to a personalized medicine approach for at least two of its therapeutic programs: the EGFR-targeted antibody-drug ...

The debt refinancing follows the firm's recent trouble with the FDA and efforts to refocus its pipeline priorities, preserve resources, and meet financial obligations.

NEW YORK – Elicio Therapeutics is planning a pivotal trial of its KRAS-targeting cancer vaccine ELI-002, hoping to show that it can delay or prevent the return of RAS-mutant pancreatic and colorectal ...